Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Now researchers have discovered that a molecule — estrogen-related receptor gamma, or ESRRG — becomes hyperactive and promotes tumor cell survival in retinoblastoma. Blocking ESRRG, the team reported, kills retinoblastoma cells.
